All In Biotech

Drug Trial Radar · NCT06340633

SPI-1005 in Adults Receiving Cochlear Implant

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
Collaborators
Med-El Corporation
First posted
Apr 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear. The main question this clinical trial aims to answer is: Is drug SPI-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug SPI-1005? The clinical trial will also measure the effects of SPI-1005 on hearing, word recognition, speech discrimination, tinnitus, and vertigo outcomes after receiving a cochlear implant. The purpose for this and future clinical trials is to learn whether SPI-1005 can prevent or treat these side effects after receiving a cochlear implant. Participants will take drug SPI-1005 or placebo (a look-alike substance that contains no drug) for 6 months, starting 2 days before receiving the cochlear implant. There are 5 required in-clinic visits over 6 months for audiology and other tests. The effects of SPI-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects SPI-1005 might have.

Conditions

  • Hearing Loss
  • Cochlear Trauma

Interventions

  • EbselenDrug

    Glutathione peroxidase mimetic

  • PlaceboDrug

    Matching placebo containing excipients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAE)Time frame: 12 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.